<DOC>
	<DOC>NCT02015715</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, single ascending dose study will assess the safety, pharmacokinetics, and pharmacodynamics of RO6864018 in healthy, male, Asian and Caucasian participants. Participants will be enrolled in cohorts and randomized 8:2 to receive a single oral administration of RO6864018 or placebo. Total study duration for each participant is up to 9 weeks.</brief_summary>
	<brief_title>A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of RO6864018 in Male, Healthy, Asian Participants</brief_title>
	<detailed_description />
	<criteria>Healthy male participants of ethnic Chinese, Korean, Japanese origin or Caucasian No signs of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12lead electrocardiogram (ECG), hematology, blood chemistry, serology and urinalysis Body Mass Index (BMI) between 18 to 30 kilograms per square meter (kg/m^2) inclusive, and a weight range of 50 to 100 kilograms (kg) (110 to 220 pounds [lb]) inclusive at screening Nonsmokers, or use of less than (&lt;) 10 cigarettes (or equivalent nicotinecontaining product) per day History or symptoms of any significant disease Personal or family history of congenital long QT syndrome or sudden death Any confirmed significant allergic reactions against any drug, or multiple drug allergies (nonactive hay fever is acceptable) Positive results for antinuclear antibody (ANA), antimitochondrial antibody (AMA), antismooth muscle antibody (ASMA) and thyroid peroxidase antibody Suspicion of regular consumption of drug of abuse History (within 3 months of screening) of alcohol consumption exceeding 14 units per week on average (1 unit = 10 grams of alcohol) Participants who have received Interferon (IFN) or peginterferon within 8 weeks prior to dosing Use of any medication (prescription or over the counter [OTC], including health supplements and herbal remedies) within 2 weeks before the first dose of study medication Positive Hepatitis A immunoglobulin M antibody (HAV IgM Ab), Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab) or human immunodeficiency virus antibody (HIV Ab) at screening Donation or loss of blood of greater than 500 milliliters (mL) within 90 days prior to dosing Have participated in other clinical studies within 60 days prior to study randomization</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>